[
  {
    "ts": null,
    "headline": "Moderna, Inc. (MRNA): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Moderna, Inc. (MRNA) on Natan’s Substack. In this article, we will summarize the bulls’ thesis on MRNA. Moderna, Inc. (MRNA)’s share was trading at $26.67 as of 13th June. MRNA’s trailing P/E was 7.06 according to Yahoo Finance. Moderna’s stock has fallen nearly 94% from its pandemic-era highs, reflecting deep […]",
    "url": "https://finnhub.io/api/news?id=8a3c21cc58f8fe7d7d647781c83ecbde182aa979f1b9bfcbc57a7a02d54bf343",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750796864,
      "headline": "Moderna, Inc. (MRNA): A Bull Case Theory",
      "id": 135512185,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Moderna, Inc. (MRNA) on Natan’s Substack. In this article, we will summarize the bulls’ thesis on MRNA. Moderna, Inc. (MRNA)’s share was trading at $26.67 as of 13th June. MRNA’s trailing P/E was 7.06 according to Yahoo Finance. Moderna’s stock has fallen nearly 94% from its pandemic-era highs, reflecting deep […]",
      "url": "https://finnhub.io/api/news?id=8a3c21cc58f8fe7d7d647781c83ecbde182aa979f1b9bfcbc57a7a02d54bf343"
    }
  },
  {
    "ts": null,
    "headline": "Moderna RSV Vaccine Gains Expanded FDA Approval for Younger Adults",
    "summary": "Moderna Inc. (NASDAQ:MRNA) is one of the best mid cap growth stocks to invest in now. On June 12, the US FDA expanded the approval for Moderna’s respiratory syncytial virus/RSV vaccine, mRESVIA (mRNA-1345). The vaccine is now approved for the prevention of lower respiratory tract disease/LRTD caused by RSV in individuals aged 18 to 59 […]",
    "url": "https://finnhub.io/api/news?id=b9969536ffcfbb97e8f7c5c2c0978fe4844199ae2b51dd89204347c27eb4e60f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750792158,
      "headline": "Moderna RSV Vaccine Gains Expanded FDA Approval for Younger Adults",
      "id": 135512186,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna Inc. (NASDAQ:MRNA) is one of the best mid cap growth stocks to invest in now. On June 12, the US FDA expanded the approval for Moderna’s respiratory syncytial virus/RSV vaccine, mRESVIA (mRNA-1345). The vaccine is now approved for the prevention of lower respiratory tract disease/LRTD caused by RSV in individuals aged 18 to 59 […]",
      "url": "https://finnhub.io/api/news?id=b9969536ffcfbb97e8f7c5c2c0978fe4844199ae2b51dd89204347c27eb4e60f"
    }
  }
]